Abstract: Disclosed is a 4,4?-dicarboxy-2,2?-bipyridine derived tridentate ligand represented by formula (I): wherein definitions of Y1, Y2, and R are the same as those defined in the specification. Also disclosed are a metal complex containing the aforesaid tridentate ligand and a dye-sensitized solar cell containing the metal complex.

Abstract: The present invention relates to phosphorescent (triplet-emitting) organometallic materials. The phosphorescent materials of the present invention comprise Ir(III)cyclometallated alkynyl complexes for use as triplet light-emitting materials. The Ir(III)cyclometallated alkynyl complexes comprise at least one cyclometallating ligand and at least one alkynyl ligand bonded to the iridium. Also provided is an organic light emitting device comprising an anode, a cathode and an emissive layer between the anode and the cathode, wherein the emissive layer comprises a Ir(III)cyclometallated alkynyl complex as a triplet emitting material.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: Copper(I) complexes for the emission of light with a structure according to formula A: wherein: M is Cu(I); L-B-L: a neutral, bidentate ligand, Z4-Z7: includes N or the fragment CR, ?with R=organic group, selected from the group consisting of: hydrogen, halogen or deuterium or groups which are bound via oxygen (—OR??), nitrogen (—NR??2), or phosphorous atoms (PR??2) as well as alkyl, aryl, heteroaryl, alkenyl, alkinyl, trialkylsilyl and triarylsilyl groups or substituted alkyl, aryl, heteroaryl and alkenyl groups with substituents such as halogens or deuterium or lower alkyl groups; X is either CR??2 or NR??; Y is either O, S or NR??; Z8 includes the fragment CR?, ?with R??O*R??, N*R??2 or P*R??2, wherein the bond to the Cu atom is carried out via these groups; R? is a sterically demanding substituent, which inhibits a change in geometry in direction to planarization of the complex in excited state, R??=organic group which is selected from the group consisting of: hydrogen, halogen or deuterium, as wel

Abstract: Compounds including a ligand L according to Formula I devices containing the same and formulations including the same are described. In Formula I, B is a 5 or 6-membered carbocyclic or heterocyclic ring; C is a condensed aromatic ring system having at least two carbocyclic or heterocyclic rings; A-B represents a bonded pair of carbocyclic or heterocyclic rings coordinated to a metal M via a nitrogen atom in ring A and an sp2 hybridized atom X6 in ring B; RA, RB and RC can represent no substitutions or the maximum substitutions available on the respective ring; X1, X2, X3, X4, X5, and X6 are carbon or nd nitrogen, and X7 is carbon; at least one of RA and RC substituents adjacent to the bond between A and C is not hydrogen; and the ligand is coordinated to a metal, having an atomic number greater than 40.

Abstract: A dendrimer compound characterized by comprising a core represented by the following formula (1-1), (1-2), (1-3), or (1-4) and at least one kind of dendritic structure selected among dendritic structures represented by the following formulae (3) and (4).

Abstract: Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process.

Abstract: In a method of stabilizing acrylic compounds, a liquid phase containing at least one acrylic compound is mixed with at least one metal and at least one ligand. The acrylic compound can be acrylic acid, methacrylic acid, and their respective esters. The metal can be copper, manganese, and cerium. The ligand can be a quinoline compound of formula (I), an N-oxide of a compound of formula (I), 2,2?-bis(2,3-dihydro-3-oxoindolylidene), or an aliphatic y-dentate ligand with y being 2-6 and comprising at least two nitrogen atoms joined by aliphatic or aromatic C1-C4 bridges comprising y-2 further coordinating nitrogen atoms or heteroatoms: where X is OH, NH2, O—(C1-C4)-alkyl, O—C(O)—(C1-C4)-alkyl, or O—C(O)-phenyl; R1 is H, or (C1-C4)-alkyl; R2 is H, (C1-C4)-alkyl, Cl, Br, or SO3H; and R3 is H, Cl or Br.

Abstract: The invention describes electronic devices comprising a metal complex compound having at least one anionic ligand containing two P donors, having the formula (I), in which R1 to R4 are, independently of one another, an atom or radical from the group comprising hydrogen, a halogen, R, RO—, RS—, RCO—, RCOO—, RNH—, R2N—, RCONR— and —Si(R)X(OR)3-X, where R=a C1-C40-hydrocarbon and X=1, 2 or 3, and E is a bridge atom from the group with carbon or boron, where an atom or radical from the group with hydrogen, halogen, —CN, R, RO—, RS—, RCO—, RCOO—, RNH—, R2N—, RCONR— and —Si(R)X(OR)3-X, where R=the C1-C40-hydrocarbon and X=1, 2 or 3, is optionally bonded to the carbon, and two radicals from the group with halogen, R, RO—, RS—, RCO—, RCOO—, RNH—, R2N—, RCONR— and —Si(R)X(OR)3-X, where R=the C1-C40-hydrocarbon and X=1, 2 or 3, are optionally bonded to the boron.

Abstract: The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: A six-coordinated ruthenium complex is represented by the following formula (I): RuL1L2L3??(I) wherein L1 represents a 2,2?-bipyridine-based bidentate ligand having at least two functional groups selected from COOH, a carboxylate group and the combination thereof; and L2 and L3 independently represent a 1-(haloalkylpyrazole)-isoquinoline-based bidentate ligand of formula (II) or formula (III).

Abstract: The present invention relates, inter alia, to metal complexes having improved solubility, process for the preparation of the metal complexes, devices comprising these metal complexes, and the use of the metal complexes.

Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.

Abstract: Novel iridium-based Ir (III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in electrochemiluminescence based detection of an analyte.

Abstract: The present invention relates generally to methods and compositions for reducing Interleukin-4 or Interleukin-13 signaling, in particular to treat asthma and atopic dermatitis. The inventors have found that Rac/PAK mediated endocytosis of the ligand bound type I (IL-4R with the chains IL-4Ra and IL-2-Rg) and/or type II receptor (IL-13R with the chains IL-4Ra and IL-13Ra1) is needed for the IL-4 and/or IL-13 mediated activation of downstream signalling events including phosphorylation of Stat family transcrition factors. These discoveries enable new methods of screening compounds that modulate Interleukin-4 and Interleukin-13 signalling, as well as new methods for treating conditions characterized by increased Interleukin-4 and Interleukin-13 levels. These conditions include inflammatory conditions, asthma bronchiale, atopic dermatitis, allergies, atopic syndromes, allergic rhinitis, and th2-induced conditions.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin.

Abstract: An organometallic compound and an organic light-emitting diode (OLED) including the organometallic compound are provided. In exemplary embodiments, the organometallic compound is a platinum complex comprising one or two heterocyclic ligands, the heterocyclic ligands being the same or different if they are two in number, each heterocyclic ligand comprising two nitrogen heterocyclic rings connected by a single bond, one of the rings being six membered and comprising at least one nitrogen and the other ring being a 1,2-diazole or a 1,2,4-triazole ring. One or two other organic ligands may be attached to the central platinum atom in the complex. OLEDs including one of the subject platinum compounds in a light emission layer exhibit lower driving voltages, higher luminances, higher efficiencies and longer lifetimes than do comparative OLEDs built with established dopants incorporated into the light emitting layers.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: The present invention provides a metal complex containing a cation represented by [(MII)2(MI)2(LC)2(LB)4]2+ [in the aforementioned formula, MII is PtII or PdII, MI is H+, AuI, AgI, CuI, HgI, TlI or PbI, and LC and LB are ligands]. The metal complex of the present invention is useful as a light emitting material of an organic EL device.

Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

Abstract: A red phosphorescent compound has the following formula: wherein is and R1 is selected from a group including C1˜C6 alkyl, C1˜C6 alkoxy, trimethylsilyl, trifluoromethyl, halogen and cyanide, and wherein each of R2, R3, R4 and R5 is independently selected from a group including hydrogen, C1˜C6 alkyl, C1˜C6 alkoxy, halogen, trimethylsilyl and trifluoromethyl.

Abstract: The invention relates to dimeric copper(I) complexes according to formula A, in particular as emitters in optoelectronic devices such as organic light emitting diodes (OLEDs) and other devices wherein: Cu: Cu(I), X: Cl, Br, I, SCN, CN, and/or alkynyl and P?N: a phosphine ligand substituted with a N-heterocycle.

Abstract: Novel polydentate carbene complexes of ruthenium and formulations containing the same are provided. Organic light emitting device containing the novel polydentate carbene complexes of ruthenium in an emissive layer are also provided. The novel polydentate carbene complexes of ruthenium may be particularly useful in OLEDs to provide devices having improved performance.

Abstract: A green phosphorescent iridium complex represented by Formula (I) is provided. In Formula (I), R1, R2 and R3 are, independently, hydrogen, halogen, substituted or non-substituted C1-6 alkyl, C1-6 alkoxy, cycloalkyl, substituted or non-substituted aryl, amino or heteroaryl, and L is a heterocyclic ring containing N—N or N—O ligand. The invention also provides a method for fabricating the green phosphorescent iridium complex and an organic light-emitting diode including the green phosphorescent iridium complex.

Abstract: An organometallic complex represented by Chemical Formula 1: wherein M, CyN, CyC, X1, X2, R1 to R4, R? and n are described in the specification.

Abstract: A light-emitting material comprises iridium and at least one ligand represented by the following formula: wherein R11 and R12 each represents an alkyl group, an aryl group, a heteroaryl group, an alkoxy group, a cyano group or a cyclic structure obtained by connection of one of a plurality of R11s to another of said plurality of R11s, or one of a plurality of R12s to another of said plurality of R12s, or one of the R11s to one of the R12s; m1 represents an integer from 0 to 4; m2 represents an integer from 0 to 6.

Abstract: Bridged cyclometalated carbene complexes, a process for preparing the bridged cyclometalated carbene complexes, the use of the bridged cyclometalated carbene complexes in organic light-emitting diodes, organic light-emitting diodes comprising at least one inventive bridged cyclometalated carbene complex, a light-emitting layer comprising at least one inventive bridged cyclometalated carbene complex, organic light-emitting diodes comprising at least one inventive light-emitting layer and devices which comprise at least one inventive organic light-emitting diode.

Abstract: Organometallic compounds and organic electroluminescence devices and compositions employing the same are provided. The organic metal compound has a chemical structure represented by formula (I) or formula (II): wherein, R is an alkyl group, or cycloalkyl group, such as C1-12 alkyl group, or C4-12 cycloalkyl group.

Abstract: Disclosed are an organometallic complex, and an organic electroluminescence device and a display device including the same. The organometallic complex is represented by the following Chemical Formula 1. The definition of the above Chemical Formula 1 is the same as described in the detailed description.

Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.

Abstract: The invention relates to a method for producing metal complexes of formula (2) [MaLxXn]Ym (2), where M is a metal from the group consisting of Mn(II), Mn(III), Mn(IV), Fe(II), Fe(III) or Fe(IV), X is a coordinating compound selected from mono-, bi- or tri-charged anions or neutral molecules which can coordinate to a metal in mono-, bi- or tri-dentate form, Y represents a non-coordinating counter-ion which ensures charge equalization of the complex, L represents a ligand of formula (1) or the protonized or de-protonized form thereof, and a, x, n, m, R, R1, R2, R3 and z have the meanings described in claim 1. Said method is characterized in that the reaction of one or more ligands of formula (1) with an iron salt or manganese salt is carried out in an acetone/water mixture in a temperature range from 0 to 50° C.

Abstract: A new ferrous complex capable of being used as an electron transfer mediator for a glucose sensor, a biosensor, and the like, is provided, which measure a glucose concentration in blood, in which the new ferrous complex exchanges rapidly and smoothly an electron between an enzyme and electrode, is strongly absorbed into electrode, and is stable, so that the new ferrous complex allows excellent sensitivity of a glucose sensor to be maintained.

Abstract: The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.

Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

Abstract: A ruthenium complex for a dye-sensitized solar cell includes a chemical formula represented by Formula (I): RuL1L2L3??(I) where L1 represents a monodentate ligand; L2 represents a tridentate ligand of and L3 represents a bidentate ligand of where R1 to R27 have meaning as defined in the specification.

Abstract: The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same.

Abstract: Novel organic compounds comprising a substituted anthracene or acridine ligand are provided. In particular, the compound includes an anthracene ligand substituted at the 9 and 10 positions. The compound may be used in organic light emitting devices to provide devices having improved efficiency and lifetime. In particular, these compounds may be especially beneficial for use in blue-emitting OLEDs.

Abstract: The present invention discloses: (i) the novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; (ii) methods of synthesis of said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts; (iii) pharmaceutically-acceptable formulations comprising said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; and (iv) methods of administration of said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof to subjects in need thereof, including subjects with cancer.

Abstract: Compounds and uses of the compounds are provided. The compounds can be used as Fe(II) sequestering compounds. For example, these compounds can be used to sequester Fe(II) in cells, organs, vasculature, or tissues. Also, provided are compositions and methods of using the them for sequestering Fe(II) in an individual. The compounds can be used as MRI paraCEST contrast agents.

Abstract: A method of staining a poly(amino acid) by contacting a poly(amino acid) with an overall neutral or overall cationic complex of at least one of transition metal ion, and a plurality of donor ligands each of which is fully coordinated to the transition metal ion and is either a nitrogen donor ligand or a cyclometalated donor ligand, such that at least one of the donor ligands is a cyclometalated donor ligand. Nitrogen donor ligands will contain heteroaryl ring systems having from 10 to 40 ring atoms, wherein each nitrogen donor ligand is substituted with from 0 to 4 R1 groups. Cyclometalated donor ligands will likewise contain heteroaryl ring systems having from 10 to 40 ring atoms, such that at least one ring atom is N, wherein each cyclometalated donor ligand is substituted with from 0 to 4 R1 groups. R1, R2, R3 and R4 groups are defined herein.

Abstract: Described herein are fluorinated organic compounds and methods of making fluorinated organic compounds, for example, using palladium complexes. Also described herein are compositions and kits containing compounds and palladium complexes described herein.

Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.

Abstract: The present invention relates to a binuclear ruthenium complex dye having a higher absorption coefficient and capable of absorbing light of longer wavelength for realizing a photoelectric conversion element and a photochemical cell which may convert solar light into electricity over a wide wavelength range and exhibit high photoelectric conversion efficiency; and a binuclear ruthenium complex dye for realizing a photoelectric conversion element and a photochemical cell which may have high durability.

Abstract: The invention relates to a process for preparing a propiolic acid or a derivative thereof by reacting a terminal alkyne with carbon dioxide, which comprises performing the reaction in the presence of a base and a copper complex, especially a copper (I) complex having at least one ligand, at least one of the ligands of the copper complex being selected from monodentate ligands which have an aminic or iminic nitrogen atom capable of coordination with copper, and polydentate ligands having at least two atoms or atom groups which are capable of simultaneous coordination with copper and are selected from nitrogen, oxygen, sulfur, phosphorus and carbene carbon.

Abstract: A red phosphorescent compound of Formula I: wherein is and R1, R2, R3, R4 and R5 are as defined in the specification.

Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Abstract: A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group VIII transition metals iron, ruthenium or osmium, with the benzo[h]quinoline ligands acting as tridentate ligands. The complexes described are proved to be very active catalysts for the reduction of ketones and aldehydes to alcohols, via hydrogen transfer and hydrogenation reactions. These compounds hence can be usefully employed as catalysts in said reduction reactions.

Abstract: [Problem] The present invention aims to provide a novel organometallic compound that can be used as a general-use highly active catalyst with superior selectivity for functional groups. [Means for Solving Problem] The present invention relates to an organometallic compound having a novel specific structure of general formula (1): and to a general-use highly active catalyst used in reductive amination reaction with superior selectivity for functional groups that comprises said organometallic compound, and to a process for preparing amine compounds by reductive amination reaction using said catalyst.

Abstract: Compositions of the invention include tunable metal-based thiophene photodynamic compounds useful as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology including cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection.